Pyridoxine (vitamin B6) is included in the Brello semaglutide formulation primarily for its potential to reduce nausea and support energy metabolism
A recent study found that patients using compounded GLP-1s had a 2.35 times higher risk of hospitalization compared to those on approved versions
We can repeat this medical success story for semaglutide. The researchers warned that cheaper treatments would not address the structural drivers of obesity, including food insecurity, poverty, urbanisation and commercial food environments, and said that coordinated policies and procurement planning would be needed to realise the benefits
These observations support growing evidence that semaglutide's effects extend beyond weight management and glucose control, while also highlighting that weight loss alone may not be an adequate surrogate for predicting cardiovascular benefit
Second, compounded products do not undergo FDA review for safety, efficacy, or manufacturing quality